COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Third Year in a Row – Zoe Financial Wins NerdWallet’s 2024 Best-of Awards for Best Online Financial Advisor
Zoe Financial, a prominent player in the financial industry, has been honored as NerdWallet's Best Online Financial Advisor for the third consecutive year in 2024. The company's commitment to leveraging technology and delivering exceptional client experiences has been recognized through the prestigious award. Learn more about Zoe Financial's mission and innovative approach at www.zoefin.com. -
COMMUNIQUÉ DE PRESSE
ElementalTV and Safe Exchange Come Together to Provide Advanced Brand Safety Tools to Publishers
Safe Exchange, owned by A Parent Media Co. Inc. (APMC), announces the integration of AdCurate Ad Safety data into ElementalTV's product suite for real-time, high-efficacy ad blocking. This collaboration provides advanced tools for Ad Safety, including real-time, actionable metadata for inbound video ads, and support for advanced political advertising content data. The integration aims to enhance monetization potential for publishers and navigate the complexities of political ad spending. For more information, visit www.safex.tv. -
COMMUNIQUÉ DE PRESSE
ERC World NFT Marketplace Set to Launch in 2024 with Competitive Transaction Fees and Exciting Features
ERC World is set to launch an innovative NFT marketplace in early 2024, offering a competitive transaction fee of 1.33% and a variety of features including unique NFT collections, an educational academy, and B2B services. The platform aims to provide a cost-effective and inclusive NFT trading experience while prioritizing accuracy and transparency. Creators, collectors, and businesses are invited to join this new era in NFT trading. For more information, visit ercworld.io. -
COMMUNIQUÉ DE PRESSE
Web3 Ventures Announces Rebranding, Changes Name to Orthogonal Global Group
Web3 Ventures Inc., a diversified investment company, announces a change of name to Orthogonal Global Group Inc. and a new stock symbol 'OGG' on the Canadian Securities Exchange. The rebranding reflects the company's commitment to investing in innovative healthcare solutions, tokenization of real world assets, and technologies that propel positive global change. The company remains dedicated to fostering innovation, supporting disruptive ideas, and uniting a community of like-minded individuals committed to driving change on a global scale. -
COMMUNIQUÉ DE PRESSE
The Motor Enclave Tampa Announces Partnership With Pirelli Tire North America
The Motor Enclave has announced a sponsorship agreement with Pirelli Tire North America to brand the Pit Lane as 'The Pirelli Pit Lane'. The 1.6 mile Hermann Tilke designed performance circuit will feature Pirelli branding and a visually stunning 'Pirelli Podium'. Pirelli, known for innovation and quality, aligns with The Motor Enclave's mission to build the premier motorsports venue in the world. The partnership will allow Pirelli to showcase its full product line and demonstrate its cutting-edge technology at the venue in Tampa, Florida. -
COMMUNIQUÉ DE PRESSE
IPQS and Phonexa Announce Partnership to Fight Affiliate Fraud With Data-Driven, Real-Time Threat Intelligence
IPQS, a leading fraud prevention platform, has partnered with Phonexa, a renowned performance and partner marketing technology firm, to combat affiliate fraud. This collaboration aims to provide businesses with real-time lead verification, protection against bot-generated leads, and streamlined operations for maximizing ROI. The partnership will offer advanced fraud detection, bot identification, superior lead quality, streamlined operations, and increased trust, benefiting clients in the fight against fraudulent activities. -
COMMUNIQUÉ DE PRESSE
Azarga Metals and Sabre Gold Mines Re-Structure Agreement
Azarga Metals Corp. has reached terms with Sabre Gold Mines Corp. to restructure the terms of the Marg Project acquisition in Central Yukon. The agreement includes a debt forgiveness arrangement and an increase in the net smelter returns royalty. In addition, the company has granted restricted stock units and stock options to its directors and officers. For more information, visit Azarga Metals' website. -
COMMUNIQUÉ DE PRESSE
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Tryp Therapeutics, Inc. announces approval from the Human Research Ethics Committee (HREC) in Australia to start a groundbreaking Phase 1 clinical trial of TRP-8803, an IV-infused psilocin, in healthy human volunteers. The trial aims to optimize doses and infusion rates of IV-administered psilocin to achieve targeted blood levels and will also collect real-time EEG data to monitor changes in EEG patterns associated with the psychedelic state. This milestone is a significant advancement in psychedelic medicine and is expected to provide crucial data for future Phase 2 studies. TRP-8803, a proprietary formulation of psilocin, is anticipated to have faster onset and shorter treatment duration, aiming to treat certain neuropsychiatric disorders with more commercial feasibility. Tryp Therapeutics is also making progress with its TRP-8802 oral psilocybin clinical trial for irritable bowel syndrome patients, with patient dosing expected in the first half of 2024. -
COMMUNIQUÉ DE PRESSE
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.
